用于癌症治疗的膜蛋白结合和膜插入嵌合体
Jiamin Cai1, Sujuan Wang1, Aili Zhou1
1Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo and Biosensing, College of Chemistry and Chemical Engineering, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, People's Republic of China.
Bioconjugate chemistry
|September 16, 2025
概括
这项研究引入了新的膜蛋白向和膜插入 (MBI) 嵌合体,用于增强癌症治疗学. 这些MBI仿真体改善了在酸性瘤微环境中的药物输送和光动力疗法疗效.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 纳米技术 纳米技术
背景情况:
- 体和抗体对于癌症治疗药物至关重要,但由于非共价相互作用,它们与瘤保留作斗争.
- 酸性瘤微环境对药物积累和治疗有效性提出了挑战.
研究的目的:
- 开发新的膜蛋白向和膜插入 (MBI) 嵌合体,以改善癌症治疗学.
- 为了增强治疗剂的输送,如e6 (Ce6) 进入瘤细胞.
- 在瘤微环境中克服传统分子识别工具的局限性.
主要方法:
- 一种膜蛋白向性阿巴和一个pH响应的膜插入域 (pHLIP) 的结合.
- 创建设计用于在酸性环境中准瘤细胞的MBI模拟器.
- 在体内评估Ce6载MBI仿真体 (Sgc8-pHLIP) 的光动力学治疗疗效.
主要成果:
- 在酸性条件下,MBI仿真体证明了有效地与瘤细胞结合.
- 与对照结构相比,Sgc8-pHLIP显示显著增强光动力学治疗疗效.
- 膜向和插入的协同效应改善了药物输送和保留.
结论:
- MBI 嵌合体代表了精确癌症治疗的有希望的策略.
- 这种方法提高了癌症治疗分子识别工具的效率.
- 该研究强调了结合准和膜插入的潜力,以改进治疗术.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tail-anchoring of Proteins in the ER Membrane
3.7K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.7K
Multi-pass Transmembrane Proteins and β-barrels
6.4K
In multi-pass transmembrane proteins, the polypeptide chain crosses the membrane more than once. The transmembrane polypeptide chain either forms an α-helix or β-strand structure. α-Helix containing multi-pass transmembrane proteins are ubiquitous, whereas β-strand containing ones are mainly found in gram-negative bacteria, mitochondria, and chloroplasts.
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...
6.4K
Insertion of Single-pass Transmembrane Proteins in the RER
16.8K
Integral membrane proteins are proteins adhered to the lipid bilayer of a cell organelle or membrane. They can be of two types: transmembrane integral proteins that span the lipid bilayer and monotopic proteins that are attached to either side of the membrane but do not pass through it.
Integral transmembrane proteins possess transmembrane and extra membrane domains. The transmembrane domains are primarily made of 20-25 hydrophobic amino acids arranged in a helical secondary confirmation. These...
Integral transmembrane proteins possess transmembrane and extra membrane domains. The transmembrane domains are primarily made of 20-25 hydrophobic amino acids arranged in a helical secondary confirmation. These...
16.8K
Insertion of Multi-pass Transmembrane Proteins in the RER
17.9K
The rough ER membrane synthesizes, assembles, and embeds transmembrane proteins in diverse topologies. These proteins function as transporters or channels and can remain in the ER membrane or are sent to the Golgi complex, lysosome, and cell membrane.
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
17.9K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


